IRVINE, Calif.--(BUSINESS WIRE)--Collaboration between California Stem Cell, Inc. (CSC) and Stemina Biomarker Discovery on a study using CSC’s 96-well CardioPlateTM containing high purity human embryonic stem cell (hESC)-derived cardiomyocyte progenitor cells, has demonstrated that it can be used as a model system for investigating and predicting drug induced cardiotoxicity, officials from the firms announced today.
